Bristol-myers Squibb Compnay

E.r. Squibb & Sons, L.l.c.

Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Ono Pharmaceutical Co., Ltd.

Medarex Inc.

Medarex, L.l.c.

Five Prime Therapeutics, Inc.

Other

N.v. Organon

Mark J Selby

Alan J Korman

Mohan Srinivasan

Haichun Huang

Changyu Wang

Guodong Chen

Michelle Minhua Han

Michael Houghton

Richard Y Huang

Kent B Thudium

Nils Lonberg

Huiming Li

Heidi N Leblanc

Karla Ann Henning

Indrani Chakraborty

Mark Yamanaka

Josephine M Cardarelli

David B Passmore

Ekaterina G Deyanova

Haibin Chen

Bingliang Chen

Paul O Sheppard

Brigitte Devaux

David Y Chien

Edward L Halk

Brenda L Stevens

Angelica Medina-Selby

Susan Barnett

Doris Guenzi Coit

Alison Witte

Richard R Spaete

Christopher I Walker

Andrea Van Elsas

Jennifer Marie Mataraza

Jang Hyun Han

Jan Zur Megede

Sergio Abrignani

Arvind Rajpal

Qui-Lim Choo

Aaron Paul Yamniuk

Linda Liang

Xi-Tao Wang

Hong Liu

Katherine E Lewis

Bryan C Barnhart

Derek T O'Hagan

Dino Dina

Han Chang

Shrikant Deshpande

Jochem Gokemeijer

Alexander T Kozhich

Kyra D Zens

Xiao Min Schebye

Christine Bee

Susan Wong

Hong-An Truong

John J Engelhardt

Daniel F Ardourel

Andy X Deng

Anan Chuntharapai

Mary Diane Feingersh

Michelle Renee Kuhne

Li-Sheng Lu

Kevin R Shoemaker

Indresh K Srivastava

Thomas D Kempe

Edward Glazer

Catherine Greer

Robert L Warne

Timothy W Sproul

Byoung J Yoo

Byung S Suh

Ming Lei

Eric Chadwick

Andrew Rankin

Ying Lian

Michael Quigley

Xiang Shao

Susan Chien-Szu Wong

Karin Hartog

Liang Schweizer

Sandra V Hatcher

Sean E Doyle

Xiaodi Deng

David J Fontana

Joseph Toth

Xavier Paliard

Bing Chen

Hui-Hua Lu

Jun Zhang

Richard Yu-Cheng Huang

Hadia Lemar

Christina Maria Milburn

Patrick Guirnalda

Zhehong Cai

Marie-Michelle Navarro Garcia

Diana Yuhui Chen

Andres A Gutierrez

Kent B Thuduim

Olufemi A Adelakun

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Antibodies binding to ILT4

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Antibodies against TIM3 and uses thereof

Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist (e.g., an antibody) in combination with a TIM-4 antagonist (e.g., an antibody).

Combination of TIM-4 antagonist and PD-1 antagonist and methods of use

Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

Anti-CD27 antibodies and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.

Anti-ICOS agonist antibodies and uses thereof

The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to WIC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Anti-GITR antibodies for cancer diagnostics

Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.

Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors

Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereof

Growing community of inventors

San Francisco, CA, United States of America

Mark J Selby